1. Home
  2. RNAZ vs ASNS Comparison

RNAZ vs ASNS Comparison

Compare RNAZ & ASNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RNAZ
  • ASNS
  • Stock Information
  • Founded
  • RNAZ 2016
  • ASNS 1998
  • Country
  • RNAZ United States
  • ASNS United States
  • Employees
  • RNAZ N/A
  • ASNS N/A
  • Industry
  • RNAZ Biotechnology: Pharmaceutical Preparations
  • ASNS Telecommunications Equipment
  • Sector
  • RNAZ Health Care
  • ASNS Telecommunications
  • Exchange
  • RNAZ Nasdaq
  • ASNS Nasdaq
  • Market Cap
  • RNAZ 6.1M
  • ASNS 6.7M
  • IPO Year
  • RNAZ 2021
  • ASNS 2022
  • Fundamental
  • Price
  • RNAZ $10.97
  • ASNS $0.43
  • Analyst Decision
  • RNAZ Strong Buy
  • ASNS Strong Buy
  • Analyst Count
  • RNAZ 1
  • ASNS 1
  • Target Price
  • RNAZ $280.00
  • ASNS $5.00
  • AVG Volume (30 Days)
  • RNAZ 14.3K
  • ASNS 8.6M
  • Earning Date
  • RNAZ 08-14-2025
  • ASNS 08-14-2025
  • Dividend Yield
  • RNAZ N/A
  • ASNS N/A
  • EPS Growth
  • RNAZ N/A
  • ASNS N/A
  • EPS
  • RNAZ N/A
  • ASNS N/A
  • Revenue
  • RNAZ N/A
  • ASNS $5,265,000.00
  • Revenue This Year
  • RNAZ N/A
  • ASNS N/A
  • Revenue Next Year
  • RNAZ N/A
  • ASNS $104.77
  • P/E Ratio
  • RNAZ N/A
  • ASNS N/A
  • Revenue Growth
  • RNAZ N/A
  • ASNS N/A
  • 52 Week Low
  • RNAZ $6.15
  • ASNS $0.34
  • 52 Week High
  • RNAZ $739.20
  • ASNS $1.83
  • Technical
  • Relative Strength Index (RSI)
  • RNAZ 55.77
  • ASNS 43.67
  • Support Level
  • RNAZ $9.29
  • ASNS $0.34
  • Resistance Level
  • RNAZ $10.48
  • ASNS $0.48
  • Average True Range (ATR)
  • RNAZ 0.66
  • ASNS 0.06
  • MACD
  • RNAZ 0.02
  • ASNS -0.00
  • Stochastic Oscillator
  • RNAZ 100.00
  • ASNS 32.72

About RNAZ TransCode Therapeutics Inc.

TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.

About ASNS Actelis Networks Inc.

Actelis Networks Inc is a networking solutions company with a mission to enable communication for Internet of Things, or IoT, projects, deployed over wide areas such as cities, campuses, airports, military bases, roads, and rail. Its networking solutions use a combination of newly deployed fiber infrastructure and existing copper and coaxial lines to create a cost-effective, secure, and quick-to-deploy network. Its solutions also offer end-to-end network security to protect critical IoT data, utilizing a powerful combination of coding and encryption technologies, applied as required on both new and existing infrastructure within the hybrid-fiber-copper network. The company operates as one operating segment: developing and marketing access broadband equipment for copper and fiber networks.

Share on Social Networks: